echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > Renfu Pharmaceutical's "Midazolam Oral Solution" is about to be approved

    Renfu Pharmaceutical's "Midazolam Oral Solution" is about to be approved

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of NMPA showed that Yichang Renfu Pharmaceutical's registration application for category 3 generic drug "Midazolam Oral Solution" has changed to "Under Approval", and it is expected to be approved soon, becoming the first oral midazolam in China.


    According to the Insight database, the drug was officially included in the priority review and approval in November 2019, and is suitable for sedation, anti-anxiety, and amnesia of pediatric patients before diagnosis, treatment, endoscopic surgery, or induction of anesthesia.


    Midazolam is a sedative and hypnotic drug.


    Midazolam oral solution has been on the market for many years abroad.


    According to the Insight database, among the domestic midazolam oral solution preparations, Yichang Renfu Pharmaceutical Co.


    Image source: Insight database (https://db.


    Image source: Insight database (https://db.
    dxy.
    cn/v5/home)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.